Related Experiment Video

Updated: Jun 7, 2026

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
06:59

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Published on: May 12, 2023

Pazopanib for the treatment of patients with advanced renal cell carcinoma

Joshua M Lang1, Michael R Harrison

  • 1Carbone Cancer Center, University of Wisconsin, 7020 Wisconsin Institutes for Medical Research, Madison, WI 53705-2225, USA.

Clinical Medicine Insights. Oncology
|October 29, 2010
PubMed

Insights

Pazopanib, a tyrosine kinase inhibitor targeting angiogenesis, offers a new therapeutic strategy for advanced renal cell carcinoma. This review covers its development, clinical trials, and treatment algorithms.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Advanced renal cell carcinoma (RCC) care has seen significant progress.
  • Understanding the molecular pathogenesis of RCC, particularly angiogenesis, is key.
  • Novel therapeutic strategies have emerged based on these insights.

Purpose of the Study:

  • To review the scientific rationale for pazopanib development.
  • To discuss preclinical and clinical trials leading to pazopanib approval for advanced RCC.
  • To present recent data and ongoing trials, proposing a treatment algorithm.

Main Methods:

  • Review of scientific literature and clinical trial data.
  • Analysis of pazopanib's mechanism of action as a tyrosine kinase inhibitor.
  • Evaluation of pharmacokinetic and toxicity profiles compared to other VEGF inhibitors.

Main Results:

  • Pazopanib targets key kinases involved in angiogenesis (VEGFR, PDGFR, c-kit).
  • It demonstrates a distinct pharmacokinetic and toxicity profile.
  • Clinical trials support its efficacy in advanced renal cell carcinoma.

Conclusions:

  • Pazopanib represents a significant advancement in advanced RCC treatment.
  • Its targeted inhibition of angiogenesis offers a new therapeutic paradigm.
  • Evidence-based treatment algorithms are crucial for optimal patient management.
Keywords:
GW786034VEGFVEGFR TKIpazopanibrenal cell carcinomatyrosine kinase inhibitor

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...